Damora Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Damora Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Damora Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Damora Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Damora Therapeutics Inc (Damora Therapeutics), formerly Galecto Inc, is a biopharmaceutical company that develops therapies for the treatment of hematologic disorders. The company's pipeline products include DMR-001, an anti-mutCALR monoclonal antibody for essential thrombocythemia and myelofibrosis; DMR-002, an anti-mutCALR monoclonal antibody for mutant calreticulin-driven myeloproliferative neoplasms; and DMR-003, an anti-mutCALR × CD3 bispecific antibody for mutant calreticulin-driven myeloproliferative neoplasms. The company utilizes a targeted biologics development approach to develop disease-modifying therapies for mutant calreticulin-driven diseases through subcutaneous administration. Damora Therapeutics is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
Building 23, Suite 105, 221 Crescent Street, Waltham, Massachusetts, 02453
Website
damoratx.com
Telephone
1 781 2819020
No of Employees
7
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DMRA (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-878.8%
(2024 vs 2023)
Market Cap*
$1.3B
* As of and is in US$
Damora Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| DMR-001: Anti-mutCALR Monoclonal Antibody (mAb) |
| DMR-002: Anti-mutCALR Monoclonal Antibody (mAb) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In November, the company completed the acquisition of Damora Therapeutics Inc, a biotechnology company. |
| 2024 | Acquisitions/Mergers/Takeovers | In October, the company acquired the global rights to BRM-1420 from Bridge Medicines. |
| 2024 | Others | In October, the company announced an intensive strategic review process and determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211. |
Competitor Comparison
| Key Parameters | Damora Therapeutics Inc | Merck & Co Inc | Novartis AG | Incyte Corp | Janssen-Cilag Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United Kingdom |
| City | Waltham | Rahway | Basel | Wilmington | Buckinghamshire |
| State/Province | Massachusetts | New Jersey | Basel-Stadt | Delaware | England |
| No. of Employees | 7 | 75,000 | 75,267 | 2,844 | 1,091 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Harwin | Chairman | Executive Board | 2025 | 40 |
| Jennifer Jarrett | Chief Executive Officer; President; Director | Executive Board | 2026 | 55 |
| Sherwin Sattarzadeh | Chief Operating Officer | Senior Management | 2026 | 47 |
| Becker Hewes | Chief Medical Officer | Senior Management | 2026 | 60 |
| Garrett Winslow | Secretary; General Counsel | Senior Management | 2021 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer